A U.S. appeals court has reinstated more than 500 lawsuits against drugmaker Merck & Co. because of its osteoporosis drug Fosamax, which plaintiffs allege increases risk of thigh bone fractures, ...
The decision, which the U.S. Court of Appeals for the Third Circuit said was a close call, hinged on whether an informal ...
And the agency expanded the approval of bimekizumab (Bimzelx) to include psoriatic arthritis, non-radiographic axial spondyloarthritis, and ankylosing spondylitis, UCB Announced.
More than 500 lawsuits, which a U.S. appeals court revived on Friday, allege Merck & Co. failed to warn patients that its osteoporosis drug Fosamax raised the risk of thigh bone fractures. Separately, ...
Few companies have attracted more attention this year than Nvidia. The chipmaker is on a roll thanks to the rapid rise of ...
Reuters.com is your online source for the latest news stories and current events, ensuring our readers up to date with any ...
Reuters.com is your online source for the latest news stories and current events, ensuring our readers up to date with any ...
A U.S. appeals court revived a lawsuit on Friday by healthcare and drug industry groups challenging the first-ever U.S. law ...
Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...
A letter from the FDA rejecting Merck Sharpe & Dohme Corp.'s proposed label warning that its osteoporosis drug Fosamax could cause stress fractures doesn’t preempt state law claims alleging the ...
Pfizer Inc (NYSE: PFE) presented positive trial data for experimental drug designed for patients suffering from cancer ...
Merck and Daiichi Sankyo's HER3 antibody-drug conjugate reported a positive phase 3 result in EGFR-mutated lung cancer. Merck ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback